Arcutis Biotherapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDArcutis Biotherapeutics, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 86), indicating clear outperformance against the broad market. Earnings growth of 246% provides fundamental context to the price action. Investors should exercise caution due to high volatility (61% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $26.58 | +1.47% | ABOVE |
| 50 SMA | $27.25 | -1.02% | BELOW |
| 100 SMA | $26.33 | +2.43% | ABOVE |
| 150 SMA | $23.06 | +16.94% | ABOVE |
| 200 SMA | $20.83 | +29.49% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ARQT in an uptrend right now?
ARQT has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is ARQT overbought or oversold?
ARQT's RSI (14) is 60. The stock is in neutral territory, neither overbought nor oversold.
Is ARQT outperforming the market?
ARQT has a Relative Strength (RS) Rating of 86 out of 99. Yes, ARQT is a market leader, outperforming 86% of all stocks over the past 12 months.
Where is ARQT in its 52-week range?
ARQT is trading at $26.97, which is 85% of its 52-week high ($31.77) and 76% above its 52-week low ($11.86).
How volatile is ARQT?
ARQT has a Beta of 1.08 and 52-week volatility of 61%. It's more volatile than the S&P 500 - expect bigger swings.